Sagimet Biosciences (SGMT) Common Equity: 2023-2024
Historic Common Equity for Sagimet Biosciences (SGMT) over the last 2 years, with Sep 2024 value amounting to $170.7 million.
- Sagimet Biosciences' Common Equity rose 74.39% to $170.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $170.7 million, marking a year-over-year increase of 74.39%. This contributed to the annual value of $91.1 million for FY2023, which is N/A change from last year.
- According to the latest figures from Q3 2024, Sagimet Biosciences' Common Equity is $170.7 million, which was down 6.88% from $183.3 million recorded in Q2 2024.
- In the past 5 years, Sagimet Biosciences' Common Equity registered a high of $190.0 million during Q1 2024, and its lowest value of -$198.4 million during Q2 2023.
- Over the past 2 years, Sagimet Biosciences' median Common Equity value was $134.3 million (recorded in 2023), while the average stood at $89.1 million.
- Data for Sagimet Biosciences' Common Equity shows a peak YoY spiked of 192.38% (in 2024) over the last 5 years.
- Sagimet Biosciences' Common Equity (Quarterly) stood at $91.1 million in 2023, then skyrocketed by 74.39% to $170.7 million in 2024.
- Its Common Equity stands at $170.7 million for Q3 2024, versus $183.3 million for Q2 2024 and $190.0 million for Q1 2024.